Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ELE-Psilo+
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Eleusis
Deal Size : Undisclosed
Deal Type : Acquisition
Details : ELE-Ket+ and ELE-Psilo+ are expected to enter Phase II clinical trials for the adjunctive treatment of major depressive disorder at the end of 2021. Under the terms of the agreement, Eleusis will acquire Kalypso and its intellectual property in an all-st...
Product Name : ELE-Psilo+
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 14, 2020
Lead Product(s) : ELE-Psilo+
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Eleusis
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
